ATE209504T1 - Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase - Google Patents

Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase

Info

Publication number
ATE209504T1
ATE209504T1 AT96901386T AT96901386T ATE209504T1 AT E209504 T1 ATE209504 T1 AT E209504T1 AT 96901386 T AT96901386 T AT 96901386T AT 96901386 T AT96901386 T AT 96901386T AT E209504 T1 ATE209504 T1 AT E209504T1
Authority
AT
Austria
Prior art keywords
pct
pharmaceutical compositions
dismutase
superoxyd
compositions contain
Prior art date
Application number
AT96901386T
Other languages
English (en)
Inventor
Eric Postaire
Corinne Regnault
Monique Rock-Arveiller
Valerie Stella
Michel Brack
Jacques Sauzieres
Original Assignee
Isocell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9475077&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE209504(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isocell filed Critical Isocell
Application granted granted Critical
Publication of ATE209504T1 publication Critical patent/ATE209504T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT96901386T 1995-01-12 1996-01-12 Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase ATE209504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9500309A FR2729296B1 (fr) 1995-01-12 1995-01-12 Compositions pharmaceutiques comprenant une superoxyde dismutase
PCT/FR1996/000055 WO1996021462A1 (fr) 1995-01-12 1996-01-12 Compositions pharmaceutiques comprenant une superoxyde dismutase

Publications (1)

Publication Number Publication Date
ATE209504T1 true ATE209504T1 (de) 2001-12-15

Family

ID=9475077

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96901386T ATE209504T1 (de) 1995-01-12 1996-01-12 Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase

Country Status (8)

Country Link
US (1) US6045809A (de)
EP (1) EP0804225B1 (de)
JP (1) JP3856825B2 (de)
AT (1) ATE209504T1 (de)
DE (1) DE69617395T2 (de)
ES (1) ES2168457T3 (de)
FR (1) FR2729296B1 (de)
WO (1) WO1996021462A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759288A1 (fr) * 1997-02-12 1998-08-14 Gredeco Groupe De Rech En Derm Nouveau gel a base de gliadine
EP1024788A1 (de) * 1997-10-03 2000-08-09 Lavipharm Laboratories, Inc. Zusammensetzung enthaltend prolamin und pflanzlichen polarelipiden, verfahren zu ihrer herstellung und ihrer verwendung
FR2770843B1 (fr) * 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
CA2335736A1 (en) * 1998-06-25 1999-12-29 Lavipharm Laboratories, Inc. A device and method for the treatment of erectile dysfunction
FR2820323B1 (fr) * 2001-02-07 2004-10-08 Innoform Sa Composition dietetique et cosmetique a base de polymeres vegetaux immobilisant des actifs
FR2822381B1 (fr) 2001-03-20 2004-10-22 Bio Obtention Sc Extrait de cucumis melo enrobe et/ou microencapsule dans un agent liposoluble a base de matiere grasse
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
JP4599604B2 (ja) * 2002-04-19 2010-12-15 カーギル テクスチュアライジング ソリューションズ ドイチュラント ゲゼルシャフト ミット ベシュレクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 生体活性のリン脂質含有成分を含有するマトリックス
JP2004099459A (ja) * 2002-09-05 2004-04-02 Asama Chemical Co Ltd 抗腫瘍剤
JP2005336072A (ja) * 2004-05-25 2005-12-08 Combi Corp 腎障害抑制剤
JP5275537B2 (ja) * 2004-08-24 2013-08-28 学校法人日本医科大学 筋肉の酸化ストレス由来疾患予防経口剤
WO2006116452A1 (en) * 2005-04-22 2006-11-02 Molecular Regenix, Llc Nutritional composition comprising hyaluronic acid and superoxide dismutase and methods of making and using same
US20060257493A1 (en) * 2005-04-28 2006-11-16 Amiji Mansoor M Nanoparticulate delivery systems for treating multi-drug resistance
GB0603975D0 (en) * 2006-03-01 2006-04-05 Etren Methods and agents for reducing oxidative stress
CA2645674A1 (en) * 2006-03-15 2007-09-20 Isocell Pharma S.A. Pharmaceutical compositions comprising sods and prolamine based peptide fragments
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
EP2255787A4 (de) * 2008-02-22 2014-08-27 Katayama Chemical Ind Co Ltd Synthetische glycolipidhaltige liposomen
PT2433640T (pt) * 2010-09-24 2020-04-03 Omnivision Gmbh Composição compreendendo sod, luteína e zeaxantina
CN118217382A (zh) * 2013-03-07 2024-06-21 巴马莎研究有限责任公司 使用麦胶蛋白肽治疗癌症的套件和方法
FR3031040B1 (fr) 2014-12-29 2018-09-07 Universite De Bretagne Occidentale Procede d'obtention d'un extrait proteique concentre en superoxydase dismutase (sod)
KR20250071617A (ko) * 2023-11-15 2025-05-22 (주)바이오제닉스 단백질의 활성을 유지하기 위한 안정화 복합체 조성물 및 이의 제조방법
CN120241634A (zh) * 2025-04-02 2025-07-04 湖北普瑞汀生物科技有限公司 一种抗胃蛋白酶降解的sod制备方法及装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292964B1 (de) * 1987-05-28 1995-04-05 Hiroshi Maeda Superoxid-Dismutase-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JPH0262829A (ja) * 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
JP2937446B2 (ja) * 1990-09-14 1999-08-23 株式会社資生堂 白髪防止黒化剤
FR2711138B1 (fr) * 1993-10-12 1995-11-24 Oreal Céramides, leur procédé de préparation et leurs applications en cosmétique et en dermopharmacie.

Also Published As

Publication number Publication date
EP0804225A1 (de) 1997-11-05
US6045809A (en) 2000-04-04
FR2729296A1 (fr) 1996-07-19
DE69617395T2 (de) 2002-08-22
ES2168457T3 (es) 2002-06-16
EP0804225B1 (de) 2001-11-28
FR2729296B1 (fr) 1997-03-28
JPH10511944A (ja) 1998-11-17
WO1996021462A1 (fr) 1996-07-18
JP3856825B2 (ja) 2006-12-13
DE69617395D1 (de) 2002-01-10

Similar Documents

Publication Publication Date Title
ATE209504T1 (de) Pharmazeutische zusammensetzungen enthaltent ein superoxyddismutase
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
ATE231719T1 (de) Neue pharmazeutische formulierungen
ID28003A (id) Turunan-turunan adamantana
TR199800902T2 (xx) Ecza form�lasyonlar�.
ATE493998T1 (de) Pharmazeutische zusammensetzung mit einem exendin-4-peptid
ATE131039T1 (de) Arzneimittel in gelform in einem spender.
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
GEP20022851B (en) Flash-Melt Oral Dosage Formulation
CA2153340A1 (fr) Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens
HUP0001917A2 (hu) Sclerosis multiplex kezelése kopolimer-1 bevételével vagy inhalálásával
WO1999044608A8 (en) New use
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
DE59811768D1 (de) Pharmazeutische kombinationspräparate enthaltend erythropoietin und modifizierte hämoglobine
NO963634L (no) Antihostepreparat inneholdende et antihostemiddel og benzydamin
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
WO1999013916A3 (en) Methods and compositions for medical imaging
DE60004204D1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
ATE198481T1 (de) Bizyclische tachykinin-antagonisten, deren herstellung und deren verwendung in pharmazeutischen zusammmensetzungen
CA2273272A1 (en) Immediate release drug delivery forms
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
BR9506507A (pt) Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties